ArticleCancer control : journal of the Moffitt Cancer Center
Exploring the Role of Preoperative Systemic Therapy and Primary Resection in NSCLC With Extrathoracic Metastases: Identifying the Optimal Candidates.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn non-small cell lung cancer (NSCLC), patients with extrathoracic metastases typically have a poor prognosis, with systemic chemotherapy being the standard care. The full potential of primary resection therapy (PRT) in these patients, especially during the immunotherapy era, is not fully established. Additionally, the effectiveness of systemic preoperative therapy in this context is unclear.
methodsThis retrospective study identified NSCLC patients with extrathoracic metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2019. We compared the survival rates of those treated with just chemotherapy vs those receiving both chemotherapy and PRT.
resultsIn a study of 41 909 patients with extrathoracic metastatic NSCLC receiving chemotherapy, we found that adding PRT significantly increased overall survival (median OS post-PSM: 18 months vs 11 months,
conclusionIn both pre- and post-immunotherapy eras, patients with extrathoracic metastatic NSCLC benefit more from adding primary tumor resection to chemotherapy, especially those with preoperative systemic therapy. We created a precise nomogram to identify the best candidates for PRT among patients with extrathoracic NSCLC metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.